190 related articles for article (PubMed ID: 35276911)
1. Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown.
Cinque F; Cespiati A; Lombardi R; Costantino A; Maffi G; Alletto F; Colavolpe L; Francione P; Oberti G; Fatta E; Bertelli C; Sigon G; Dongiovanni P; Vecchi M; Fargion S; Fracanzani AL
Nutrients; 2022 Jan; 14(3):. PubMed ID: 35276911
[TBL] [Abstract][Full Text] [Related]
2. Multiplying effects of COVID-19 lockdown on metabolic risk and fatty liver.
Shanmugam H; Di Ciaula A; Di Palo DM; Molina-Molina E; Garruti G; Faienza MF; vanErpecum K; Portincasa P
Eur J Clin Invest; 2021 Jul; 51(7):e13597. PubMed ID: 34032283
[TBL] [Abstract][Full Text] [Related]
3. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
[TBL] [Abstract][Full Text] [Related]
4. The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.
Xia MF; Lin HD; Chen LY; Wu L; Ma H; Li Q; Aleteng Q; Hu Y; He WY; Gao J; Bian H; Li XY; Gao X
Diabetologia; 2019 Apr; 62(4):644-654. PubMed ID: 30673802
[TBL] [Abstract][Full Text] [Related]
5. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
6. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
7. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
8. Telemedicine as a tool for dietary intervention in NAFLD-HIV patients during the COVID-19 lockdown: A randomized controlled trial.
Policarpo S; Machado MV; Cortez-Pinto H
Clin Nutr ESPEN; 2021 Jun; 43():329-334. PubMed ID: 34024536
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
Krawczyk M; Stachowska E; Milkiewicz P; Lammert F; Milkiewicz M
Digestion; 2016; 93(2):139-48. PubMed ID: 26745555
[TBL] [Abstract][Full Text] [Related]
10. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
[TBL] [Abstract][Full Text] [Related]
11. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease.
Delik A; Akkız H; Dinçer S
Indian J Gastroenterol; 2020 Feb; 39(1):84-91. PubMed ID: 32333362
[TBL] [Abstract][Full Text] [Related]
12. PNPLA3 Expression Is Related to Liver Steatosis in Morbidly Obese Women with Non-Alcoholic Fatty Liver Disease.
Aragonès G; Auguet T; Armengol S; Berlanga A; Guiu-Jurado E; Aguilar C; Martínez S; Sabench F; Porras JA; Ruiz MD; Hernández M; Sirvent JJ; Del Castillo D; Richart C
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128907
[TBL] [Abstract][Full Text] [Related]
13. Independent and joint correlation of PNPLA3 I148M and TM6SF2 E167K variants with the risk of coronary heart disease in patients with non-alcoholic fatty liver disease.
Wu JT; Liu SS; Xie XJ; Liu Q; Xin YN; Xuan SY
Lipids Health Dis; 2020 Feb; 19(1):29. PubMed ID: 32093693
[TBL] [Abstract][Full Text] [Related]
14. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease.
Shen J; Wong GL; Chan HL; Chan RS; Chan HY; Chu WC; Cheung BH; Yeung DK; Li LS; Sea MM; Woo J; Wong VW
J Gastroenterol Hepatol; 2015 Jan; 30(1):139-46. PubMed ID: 25040896
[TBL] [Abstract][Full Text] [Related]
15. Role of the PNPLA3 I148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea.
Lee SS; Byoun YS; Jeong SH; Woo BH; Jang ES; Kim JW; Kim HY
Dig Dis Sci; 2014 Dec; 59(12):2967-74. PubMed ID: 25069572
[TBL] [Abstract][Full Text] [Related]
16. PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease.
Petta S; Valenti L; Marchesini G; Di Marco V; Licata A; Cammà C; Barcellona MR; Cabibi D; Donati B; Fracanzani A; Grimaudo S; Parrinello G; Pipitone RM; Torres D; Fargion S; Licata G; Craxì A
PLoS One; 2013; 8(9):e74089. PubMed ID: 24069270
[TBL] [Abstract][Full Text] [Related]
17. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
[TBL] [Abstract][Full Text] [Related]
18. Impact of Physical Activity Differences Due to COVID-19 Pandemic Lockdown on Non-Alcoholic Fatty Liver Parameters in Adults with Metabolic Syndrome.
Mascaró CM; Bouzas C; Montemayor S; García S; Mateos D; Casares M; Gómez C; Ugarriza L; Borràs PA; Martínez JA; Tur JA
Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745100
[TBL] [Abstract][Full Text] [Related]
19. Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease.
Bugianesi E; Bizzarri C; Rosso C; Mosca A; Panera N; Veraldi S; Dotta A; Giannone G; Raponi M; Cappa M; Alisi A; Nobili V
Am J Gastroenterol; 2017 Aug; 112(8):1277-1286. PubMed ID: 28555633
[TBL] [Abstract][Full Text] [Related]
20. PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.
Sun DQ; Zheng KI; Xu G; Ma HL; Zhang HY; Pan XY; Zhu PW; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Zheng MH
Liver Int; 2020 Jan; 40(1):107-119. PubMed ID: 31519069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
